Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers

Next Previous
X
Search
Trial Profile

Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cholesteryl palmitate/colfosceril palmitate (Primary)
  • Indications Otitis media
  • Focus Adverse reactions; First in man
  • Sponsors Novus Therapeutics

    • Most Recent Events

    • 10 Jun 2019 According to a Novus Therapeutics media release, data from this trial will be presented at the upcoming 20th International Symposium on Recent Advances in Otitis Media, being held June 9-13, 2019 in Los Angeles, CA.
    • 14 May 2019 According to a Novus Therapeutics media release, data from this study is expected in June 2019.
    • 22 Apr 2019 According to a Novus Therapeutics media release, the company expects to report data from the 14-day, dose-escalation safety and tolerability data in the coming months.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top